Increasing amniotic fluid magnesium concentrations with stable maternal serum levels: a prospective clinical trial. 2005

Limor Gortzak-Uzan, and Daphna Mezad, and Ana Smolin, and Michael Friger, and Mahmoud Huleihel, and Mordechai Hallak
Department of Obstetrics and Gynecology, Soroka University Medical Center, Faculty of Health Science, Ben Gurion University of the Negev, Beer Sheva, Israel.

OBJECTIVE To compare the effect of prolonged maternal intravenous MgSO4 administration on amniotic fluid and serum concentrations of magnesium over time in preterm labor patients. METHODS Patients at 24-34 weeks of singleton gestation who presented with contractions (> 8 in 60 minutes) underwent amniocentesis to rule out intrauterine infection after signing an informed consent form. Some of these women who were clinically judged to have preterm labor received intravenous MgSO4: a 4-g loading dose followed by a 2 g/h maintenance dose. For technical reasons some patients had amniocentesis performed before initiation of MgSO4 (controls), while others had the procedure during tocolytic therapy (study subjects). Duration of treatment until amniocentesis was recorded, and blood samples were drawn at the time of amniocentesis. Maternal serum and amniotic fluid magnesium levels were measured using a colorimetric end point method. Data were evaluated using the Student t test and linear regression analysis. RESULTS Mean magnesium levels in maternal serum rose from 1.74 +/- 0.2 mg/dL in controls to 4.01 +/- 0.4 mg/dL in the study group. Mean magnesium levels in Mean magnesium levels in amniotic fluid were 1.41 +/- 0.18 mg/dL in the controls versus 2.28 +/- 0.53 mg/dL in the treatment group. Duration of MgSO4 treatment ranged from 3 to 22 hours. Amniotic fluid magnesium concentrations increased significantly during therapy (correlation coefficient = 0.89; p < 0.001), while maternal serum levels remained stable over time (correlation coefficient between maternal serum levels and time = -0.39; p=0.34). CONCLUSIONS Although maternal serum magnesium levels remained stable with intravenous MgSO4 therapy, concentrations continued to rise in amniotic fluid over time. However, amniotic fluid magnesium levels never exceeded maternal serum concentrations during the study period.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007752 Obstetric Labor, Premature Onset of OBSTETRIC LABOR before term (TERM BIRTH) but usually after the FETUS has become viable. In humans, it occurs sometime during the 29th through 38th week of PREGNANCY. TOCOLYSIS inhibits premature labor and can prevent the BIRTH of premature infants (INFANT, PREMATURE). Preterm Labor,Labor, Premature,Premature Labor,Premature Obstetric Labor,Labor, Premature Obstetric,Labor, Preterm
D008274 Magnesium A metallic element that has the atomic symbol Mg, atomic number 12, and atomic weight 24.31. It is important for the activity of many enzymes, especially those involved in OXIDATIVE PHOSPHORYLATION.
D008278 Magnesium Sulfate A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083) Magnesium Sulfate, Heptahydrate,Heptahydrate Magnesium Sulfate,Sulfate, Magnesium
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011262 Pregnancy Trimester, Second The middle third of a human PREGNANCY, from the beginning of the 15th through the 28th completed week (99 to 196 days) of gestation. Midtrimester,Pregnancy, Second Trimester,Trimester, Second,Midtrimesters,Pregnancies, Second Trimester,Pregnancy Trimesters, Second,Second Pregnancy Trimester,Second Pregnancy Trimesters,Second Trimester,Second Trimester Pregnancies,Second Trimester Pregnancy,Second Trimesters,Trimesters, Second
D011263 Pregnancy Trimester, Third The last third of a human PREGNANCY, from the beginning of the 29th through the 42nd completed week (197 to 294 days) of gestation. Pregnancy, Third Trimester,Trimester, Third,Last Trimester,Last Trimesters,Pregnancies, Third Trimester,Pregnancy Trimesters, Third,Third Pregnancy Trimester,Third Pregnancy Trimesters,Third Trimester,Third Trimester Pregnancies,Third Trimester Pregnancy,Third Trimesters,Trimester, Last,Trimesters, Last,Trimesters, Third
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D003124 Colorimetry Any technique by which an unknown color is evaluated in terms of standard colors. The technique may be visual, photoelectric, or indirect by means of spectrophotometry. It is used in chemistry and physics. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
D005260 Female Females

Related Publications

Limor Gortzak-Uzan, and Daphna Mezad, and Ana Smolin, and Michael Friger, and Mahmoud Huleihel, and Mordechai Hallak
February 1993, Obstetrics and gynecology,
Limor Gortzak-Uzan, and Daphna Mezad, and Ana Smolin, and Michael Friger, and Mahmoud Huleihel, and Mordechai Hallak
January 1982, Journal of perinatal medicine,
Limor Gortzak-Uzan, and Daphna Mezad, and Ana Smolin, and Michael Friger, and Mahmoud Huleihel, and Mordechai Hallak
January 2009, HIV clinical trials,
Limor Gortzak-Uzan, and Daphna Mezad, and Ana Smolin, and Michael Friger, and Mahmoud Huleihel, and Mordechai Hallak
April 1985, American journal of obstetrics and gynecology,
Limor Gortzak-Uzan, and Daphna Mezad, and Ana Smolin, and Michael Friger, and Mahmoud Huleihel, and Mordechai Hallak
January 2002, Reproductive toxicology (Elmsford, N.Y.),
Limor Gortzak-Uzan, and Daphna Mezad, and Ana Smolin, and Michael Friger, and Mahmoud Huleihel, and Mordechai Hallak
July 2004, Prenatal diagnosis,
Limor Gortzak-Uzan, and Daphna Mezad, and Ana Smolin, and Michael Friger, and Mahmoud Huleihel, and Mordechai Hallak
February 1979, British medical journal,
Limor Gortzak-Uzan, and Daphna Mezad, and Ana Smolin, and Michael Friger, and Mahmoud Huleihel, and Mordechai Hallak
April 1980, British journal of obstetrics and gynaecology,
Limor Gortzak-Uzan, and Daphna Mezad, and Ana Smolin, and Michael Friger, and Mahmoud Huleihel, and Mordechai Hallak
January 2003, Fetal diagnosis and therapy,
Limor Gortzak-Uzan, and Daphna Mezad, and Ana Smolin, and Michael Friger, and Mahmoud Huleihel, and Mordechai Hallak
September 1995, American journal of obstetrics and gynecology,
Copied contents to your clipboard!